Tumor antigen presentation via dendritic cell

Tumor antigen presentation via dendritic cells is a **biological process** rather than a discrete molecular target. Dendritic cells are professional antigen-presenting cells that play a central role in initiating anti-tumor immune responses. They capture, process, and present tumor-associated antigens on major histocompatibility complex (MHC) molecules to activate T lymphocytes—both CD4+ helper T-cells via MHC class II and CD8+ cytotoxic T-cells via MHC class I through direct presentation or cross-presentation mechanisms[1][2][3]. Specialized mechanisms such as "cross-dressing" allow dendritic cells to acquire preformed peptide-MHC complexes from cancer cells for efficient stimulation of cytotoxic T-cells[1]. The effectiveness of this process is critical for successful cancer immunosurveillance and underpins several immunotherapeutic strategies including DC-based vaccines. However, the immunosuppressive tumor microenvironment often impairs dendritic cell function, limiting therapeutic efficacy unless specifically addressed by treatment approaches[3]. **Note:** This entry describes an immune pathway/process rather than an individual molecular target such as a receptor or enzyme. Therefore, it should not be considered a canonical drug target but is essential context for understanding many cancer immunotherapies.

Other names

Antigen cross-presentation by dendritic cellDendritic cell-mediated tumor antigen presentationDC cross-dressing (for specific mechanism)

Enhancement of dendritic cell function to improve tumor antigen presentation and stimulate anti-tumor T-cell responses[3]